Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease

Haematologica

Volumn 103, Issue 10, 2018, Pages e483-e485

  Chonat, Satheesh ^a,b   Quarmyne, Maa Ohui ^a,b   Bennett, Caroline M ^a,b   Dean, Christina L ^a   Joiner, Clinton H ^a,b   Fasano, Ross M ^a,b   Stowell, Sean R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AFLAC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADVERSE EVENT; BLOOD; BLOOD TRANSFUSION REACTION; CASE REPORT; COMPLEMENT ALTERNATIVE PATHWAY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOLYSIS; HUMAN; SICKLE CELL ANEMIA;

ADOLESCENT; ANEMIA, SICKLE CELL; COMPLEMENT PATHWAY, ALTERNATIVE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOLYSIS; HUMANS; TRANSFUSION REACTION;

EID: 85054362820     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2018.194670     Document Type: Note

References (16)

1. Nickel RS, Horan JT, Fasano RM, et al. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol. 2015;90(12):1135-1141.
2. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169(5):746-753.
3. Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92(12):1340-1348.
4. Habibi A, Mekontso Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol. 2016;91(10):989-994.
5. Pirenne F, Bartolucci P, Habibi A. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment. Transfus Clin Biol. 2017;24(3):227-231.
6. Ghosh S, Tan F, Yu T, et al. Global gene expression profiling of endothelium exposed to heme reveals an organ-specific induction of cytoprotective enzymes in sickle cell disease. Voolstra C, editor. PLoS One. 2011;6(3):e18399.
7. Adisa OA, Hu Y, Ghosh S, Aryee D, Osunkwo I, Ofori-Acquah SF. Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease. Br J Haematol. 2013;162(5):702-705.
8. Roumenina LT, Radanova M, Atanasov BP, et al. Heme interacts with C1q and inhibits the classical complement pathway. J Biol Chem. 2011;286(18):16459-16469.
9. Frimat M, Tabarin F, Dimitrov JD, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood. 2013;122(2):282-292.
10. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest. 2013; 123(11):4809-4820.
11. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood. 2014;123(3):377-390.
12. Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062-1064.
13. Gupta S, Fenves A, Nance ST, Sykes DB, Dzik WS. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. Transfusion. 2014;55(3):623-628.
14. Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015;55(10):2398-2403.
15. Chonat S, Chandrakasan S, Kalinyak KA, Ingala D, Gruppo R, Kalfa TA. Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab. Br J Haematol. 2016;175(4):744-747.
16. Stowell SR, Winkler AM, Maier CL, et al. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol. 2012;2012:307093.